Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217-and ALKBH5-mediated modulation of RNA methylation in breast cancer cells

Oncotarget

Volumn 7, Issue 40, 2016, Pages 64527-64542

  Zhang, Chuanzhao ^a,b   Zhi, Wanqing Iris ^a   Lu, Haiquan ^a   Samanta, Debangshu ^a   Chen, Ivan ^a   Gabrielson, Edward ^a   Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Breast cancer stem cells; Hypoxia; Metastasis; N6 methyladenosine; Pluripotency factors

Indexed keywords

ALKB HOMOLOG 5; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRUPPEL LIKE FACTOR 4; RNA METHYLTRANSFERASE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ZNF217 PROTEIN; ADENOSINE; ALKBH5 PROTEIN, HUMAN; ALKYLATED DNA REPAIR PROTEIN ALKB HOMOLOG 5; KRUPPEL LIKE FACTOR; MESSENGER RNA; N(6)-METHYLADENOSINE; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; ZNF217 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER STEM CELL; CANCER STEM CELL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RNA METHYLATION; TUMOR BIOPSY; ANALOGS AND DERIVATIVES; ANIMAL; BREAST TUMOR; CELL HYPOXIA; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; METHYLATION; PATHOLOGY; PHYSIOLOGY; SCID MOUSE;

ADENOSINE; ALKB HOMOLOG 5, RNA DEMETHYLASE; ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MCF-7 CELLS; METHYLATION; MICE; MICE, SCID; NANOG HOMEOBOX PROTEIN; NEOPLASTIC STEM CELLS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84994092353     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11743     Document Type: Article

References (48)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-3988.
2. Kreso A and Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14(3):275-291.
3. Oskarsson T, Batlle E and Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014; 14(3):306-321.
4. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-679.
5. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106(33):13820-13825.
6. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS and Arteaga CL. TGF-b inhibition enhances chemotherapy action against triplenegative breast cancer. J Clin Invest. 2013; 123(3):1348-1358.
7. Samanta D, Gilkes DM, Chaturvedi P, Xiang L and Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014; 111(50):E5429-5438.
8. Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, Bullen JW and Semenza GL. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A. 2015; 112(33):E4600-4609.
9. Hu T, Liu S, Breiter DR, Wang F, Tang Y and Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008; 68(16):6533-6540.
10. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H and Ai W. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011; 30(18):2161-2172.
11. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R and Martin AG. Sox2 expression in breast tumors and activation in breast cancer stem cells. Oncogene. 2012; 31(11):1354-1365.
12. Santaliz-Ruiz LEIV, Xie XJ, Old M, Teknos TN and Pan QT. Emerging role of nanog in tumorigenesis and cancer stem cells. Int J Cancer. 2014; 135(12):2741-2748.
13. Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X and Semenza GL. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016; 113(14):E2047-E2056.
14. Thalhammer A, Bencokova Z, Poole R, Loenarz C, Adam J, O'Flaherty L, Schodel J, Mole D, Giaslakiotis K, Schofield CJ, Hammond EM, Ratcliffe PJ and Pollard PJ. Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor 1a (HIF-1a). PloS One. 2011; 6(1):e16210.
15. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vagbo CB, Shi Y, Wang WL, Song SH, Lu Z, Bosmans RP, Dai Q, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013; 49(1):18-29.
16. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012; 109(8):2784-2789.
17. Xiang L, Gilkes DM, Hu H, Takano N, Luo W, Lu H, Bullen J, Samanta D, Liang H and Semenza GL. Hypoxiainducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2014; 5(24):12509-12527. doi: 10.18632/oncotarget.2997.
18. Fu Y, Dominissini D, Rechavi G and He C. Gene expression regulation mediated through reversible m6A RNA methylation. Nat Rev Genet. 2014; 15(5):293-306.
19. Lee M, Kim B and Kim VN. Emerging roles of RNA modification: m6A and U-tail. Cell. 2014; 158(5):980-987.
20. Littlepage LE, Adler AS, Kouros-Mehr H, Huang GQ, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJP, et al. The transcription factor znf217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012; 2(7):638-651.
21. Mao XG, Yan M, Xue XY, Zhang X, Ren HG, Guo G, Wang P, Zhang W and Huo JL. Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. Lab Invest. 2011; 91(7):1068-1078.
22. Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Bieche I, Grisard E, Josserand V, Coll JL, Roux P, Corbo L, Treilleux I, Rimokh R, et al. ZNF217 Is a marker of poor prognosis in breast cancer that drives epithelialmesenchymal transition and invasion. Cancer Res. 2012; 72(14):3593-3606.
23. Aguilo F, Zhang F, Sancho A, Fidalgo M, Di Cecilia S, Vashisht A, Lee DF, Chen CH, Rengasamy M, Andino B, Jahouh F, Roman A, Krig SR, et al. Coordination of m6A mRNA methylation and gene transcription by Zfp217 regulates pluripotency and reprogramming. Cell Stem Cell. 2015; 17(6):689-704.
24. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6):515-527.
25. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, et al. ALDH1 Is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1(5):555-567.
26. Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, Gilkes DM, He J and Semenza GL. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A. 2015; 112(45):E6215-6223.
27. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME and Semenza GL. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med. 2012; 90(7):803-815.
28. Zhang H, Wong CCL, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT, Jr., Raman V, Zhen L, Mitzner WA, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene. 2012; 31(14):1757-1770.
29. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-5511.
30. Vaupel P, Mayer A and Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol. 2004; 381:335-354.
31. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47.
32. Pries AR, Hopfner M, le Noble F, Dewhirst MW and Secomb TW. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer. 2010; 10(8):587-593.
33. Semenza GL. The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta. 2015; 1863(3):382-391.
34. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, Hubaud A, Stadler B, Choi M, Bar M, Tewari M, Liu A, Vessella R, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 2011; 71(13):4640-4652.
35. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN. Hypoxiainducible factor 1a promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 2012; 14(1):R6.
36. Iriondo O, Rabano M, Domenici G, Carlevaris O, Lopez-Ruiz JA, Zabalza I, Berra E and Vivanco MD. Distinct breast cancer stem/progenitor cell populations require either HIF-1a or loss of PHD3 to expand under hypoxic conditions. Oncotarget. 2015; 6(31):31721-31739. doi: 10.18632/oncotarget.5564.
37. Brooks DL, Schwab LP, Krutilina R, Parke DN, Sethuraman A, Hoogewijs D, Schorg A, Gotwald L, Fan M, Wenger RH and Seagroves TN. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer. 2016; 15:26.
38. Rodenhiser DI, Andrews JD, Vandenberg TA and Chambers AF. Gene signatures of breast cancer progression and metastasis. Breast Cancer Res. 2011; 13(1):201.
39. Batista PJ, Molinie B, Wang J, Qu K, Zhang J, Li L, Bouley DM, Lujan E, Haddad B, Daneshvar K, Carter AC, Flynn RA, Zhou C, et al. m6A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell. 2014; 15(6):707-719.
40. Petruzzelli R, Christensen DR, Parry KL, Sanchez-Elsner T and Houghton FD. HIF-2a regulates NANOG expression in human embryonic stem cells following hypoxia and reoxygenation through the interaction with an Oct-Sox cis regulatory element. PloS One. 2014; 9(10):e108309.
41. Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014; 76:39-56.
42. Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D and Semenza GL. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci U S A. 2014; 111(3):E384-393.
43. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, Ng IO, Wirtz D and Semenza GL. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A. 2011; 108(39):16369-16374.
44. Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S and Brodie AH. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast cancer Res. 2014; 16(1):R15.
45. Jia X, Hong Q, Lei L, Li D, Li J, Mo M, Wang Y, Shao Z, Shen Z, Cheng J and Liu G. Basal and therapydriven hypoxia-inducible factor-1a confers resistance to endocrine therapy in estrogen receptor-positive breast cancer. Oncotarget. 2015; 6(11):8648-8662. doi: 10.18632/oncotarget.3257.
46. Yang J, AlTahan A, Jones DT, Buffa FM, Bridges E, Interiano RB, Qu C, Vogt N, Li JL, Baban D, Ragoussis J, Nicholson R, DavidoffAM, et al. Estrogen receptor-alpha directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proc Natl Acad Sci U S A. 2015; 112(49):15172-15177.
47. Dominissini D, Moshitch-Moshkovitz S, Salmon-Divon M, Amariglio N and Rechavi G. Transcriptome-wide mapping of N6-methyladenosine by m6A-seq based on immunocapturing and massively parallel sequencing. Nat Protoc. 2013; 8(1):176-189.
48. National Research Council. Guide for the Care and Use of Laboratory Animals, Eighth Edition. The National Academies Press: Washington, D.C., 2011.